Literature DB >> 24504593

How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes.

Joëlle St-Pierre1, Kris Chadee.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24504593     DOI: 10.1007/s10620-014-3042-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  33 in total

Review 1.  The pathophysiology of tumor necrosis factors.

Authors:  P Vassalli
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 2.  Signalling pathways of the TNF superfamily: a double-edged sword.

Authors:  Bharat B Aggarwal
Journal:  Nat Rev Immunol       Date:  2003-09       Impact factor: 53.106

Review 3.  Towards personalized care in IBD.

Authors:  Mark E Gerich; Dermot P B McGovern
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-12-17       Impact factor: 46.802

Review 4.  Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.

Authors:  Poonam Dharmani; Kris Chadee
Journal:  Curr Mol Pharmacol       Date:  2008-11       Impact factor: 3.339

Review 5.  Role of cytokines in the pathogenesis of inflammatory bowel disease.

Authors:  K A Papadakis; S R Targan
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

6.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies.

Authors:  D Kontoyiannis; M Pasparakis; T T Pizarro; F Cominelli; G Kollias
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

7.  Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR.

Authors:  M Komatsu; D Kobayashi; K Saito; D Furuya; A Yagihashi; H Araake; N Tsuji; S Sakamaki; Y Niitsu; N Watanabe
Journal:  Clin Chem       Date:  2001       Impact factor: 8.327

8.  Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

Authors:  E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

9.  Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts.

Authors:  P E Hass; A Hotchkiss; M Mohler; B B Aggarwal
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

10.  NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy.

Authors:  Jan Hendrik Niess; Jochen Klaus; Johannes Stephani; Carolin Pflüger; Nadine Degenkolb; Ulrike Spaniol; Benjamin Mayer; Georgia Lahr; Georg B T von Boyen
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

View more
  1 in total

1.  Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.

Authors:  Jieun Kang; Dae Hyun Jeong; Minkyu Han; Suk-Kyun Yang; Jeong-Sik Byeon; Byong Duk Ye; Sang Hyoung Park; Sung Wook Hwang; Tae Sun Shim; Kyung-Wook Jo
Journal:  J Korean Med Sci       Date:  2018-10-23       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.